P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES
Introduction: Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with dismal prognosis and increasing incidence. Information on epidemiology and risk factors are scarce, particularly in Latin America. Aim: Describe and analyze a multicentric cohort of CCA patients from Latin...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-09-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268121000752 |
| _version_ | 1819020686890369024 |
|---|---|
| author | Leonardo G. da Fonseca Laura Izquierdo-Sanchez Pedro H. Hashizume Estefanía Liza Beca Yanina Carlino Enrique Carrera Marco Arrese Javier Díaz Ferrer Domingo Balderramo Flair J. Carrilho Andre Boonstra Jose D. Debes Claudia Pinto Marques Souza de Oliveira Jesus M. Banales |
| author_facet | Leonardo G. da Fonseca Laura Izquierdo-Sanchez Pedro H. Hashizume Estefanía Liza Beca Yanina Carlino Enrique Carrera Marco Arrese Javier Díaz Ferrer Domingo Balderramo Flair J. Carrilho Andre Boonstra Jose D. Debes Claudia Pinto Marques Souza de Oliveira Jesus M. Banales |
| author_sort | Leonardo G. da Fonseca |
| collection | DOAJ |
| description | Introduction: Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with dismal prognosis and increasing incidence. Information on epidemiology and risk factors are scarce, particularly in Latin America. Aim: Describe and analyze a multicentric cohort of CCA patients from Latin America. Methods: The Ibero-Latin American Research Network on Cholangiocarcinoma (ILARN-CCA) Registry and ESCALON consortium (www.escalon.eu) collected data from patients diagnosed from 2010 and onwards. Results: 183 patients with histologically/cytologically confirmed CCA were included from 5 tertiary hospitals (Brazil,Argentina,Chile,Ecuador and Peru). Median age at diagnosis was 62 years-old (IQR:25-87) and 55.7% were women. Most frequent risk factors were overweight/obesity (n=68;31.1%), diabetes (n=35;19.1%), NAFLD (n=14;7.7%), viral hepatitis (n=5;2.7%), cirrhosis (n=4;2.2%), gallstones (n=10;5.5%), primary sclerosing cholangitis (n=11;6%) and 21.3%(n=39) had no known-risk factor. Intrahepatic CCA was the predominant type (n=73;39.9%), followed by distal (n=49;26.8%) and perihilar (n=38;20.8%). Regional lymph-node invasion was found in 74 (40.4%) and metastasis in 79 (43.2%) patients. Upon diagnosis, 88 patients (48.1%) required upfront biliary stenting prior to main treatments, consisting in resection (n=39;21.3%) or palliative modalities (n=135;73.8%). Recurrence occurred in 64.1%(n=25), with median time-to-recurrence of 13.5 months (95%CI:6.5-18.8). Chemotherapy was delivered to 120 patients (Gemcitabine+Cisplatin:n=105;87.5%) with a median progression-free survival of 4.2 months (95%CI:3.4-4.9). Median overall survival of the entire cohort was 8.2 months (n=183;95%CI:6.3-10.2), 22.5 (n=39;95%CI:11.6-34.1) under surgery, 10.4 (n=87;95%CI:8.4-13.6) under chemotherapy and 2.5 (n=30;95%CI:1.5-3.9) without active treatments (log-rank p<0.001). Conclusion: CCA is associated to diverse etiologies in Latin-America, particularly metabolic disorders. Surgical resection shows favorable outcome, highlighting the need of surveillance strategies in individuals at risk. |
| first_indexed | 2024-12-21T03:55:10Z |
| format | Article |
| id | doaj.art-89648a0f10ac4da28426b1a3f5ca9461 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-21T03:55:10Z |
| publishDate | 2021-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-89648a0f10ac4da28426b1a3f5ca94612022-12-21T19:16:51ZengElsevierAnnals of Hepatology1665-26812021-09-0124100376P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMESLeonardo G. da Fonseca0Laura Izquierdo-Sanchez1Pedro H. Hashizume2Estefanía Liza Beca3Yanina Carlino4Enrique Carrera5Marco Arrese6Javier Díaz Ferrer7Domingo Balderramo8Flair J. Carrilho9Andre Boonstra10Jose D. Debes11Claudia Pinto Marques Souza de Oliveira12Jesus M. Banales13São Paulo Clínicas Liver Cancer GroupClinical Oncology; Instituto do Câncer do Estado de São Paulo, University of Sao Paulo, BrazilDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, SpainInstituto do Câncer do Estado de São Paulo, University of Sao Paulo, BrazilDepartamento del Aparato Digestivo, Hospital Edgardo Rebagliati-EsSaludGastroenterology Department, Hospital Privado Universitário de Córdoba, Instituto Universitario de Ciências Biomédicas de Córdoba, Córdoba, ArgentinaDepartment of Gastroenterology and Hepatology, Hospital Eugenio Espejo, Quito, EcuadorDepartamento de Gastroenterología, Facultad de Medicina, and Centro de Envejecimiento y Regeneracion (CARE), Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento del Aparato Digestivo, Hospital Edgardo Rebagliati-EsSalud; Facultad De Medicina. Universidad Nacional Mayor de San Marcos, Lima -PerúGastroenterology Department, Hospital Privado Universitário de Córdoba, Instituto Universitario de Ciências Biomédicas de Córdoba, Córdoba, ArgentinaSão Paulo Clínicas Liver Cancer GroupClinical Oncology; Hospital das Clínicas Complex, Division of Clinical Gastroenterology and Hepatology, Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, BrazilDepartment of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, NLDepartment of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, NL; Department of Medicine, University of Minnesota, Minneapolis, MN, USDepartment of Gastroenterology, Clinical Division, Hepatology Branch, University of São Paulo School of Medicine, São Paulo, BrazilDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain; Ikerbasque, Basque Foundation for Science, 48013 Bilbao, SpainIntroduction: Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with dismal prognosis and increasing incidence. Information on epidemiology and risk factors are scarce, particularly in Latin America. Aim: Describe and analyze a multicentric cohort of CCA patients from Latin America. Methods: The Ibero-Latin American Research Network on Cholangiocarcinoma (ILARN-CCA) Registry and ESCALON consortium (www.escalon.eu) collected data from patients diagnosed from 2010 and onwards. Results: 183 patients with histologically/cytologically confirmed CCA were included from 5 tertiary hospitals (Brazil,Argentina,Chile,Ecuador and Peru). Median age at diagnosis was 62 years-old (IQR:25-87) and 55.7% were women. Most frequent risk factors were overweight/obesity (n=68;31.1%), diabetes (n=35;19.1%), NAFLD (n=14;7.7%), viral hepatitis (n=5;2.7%), cirrhosis (n=4;2.2%), gallstones (n=10;5.5%), primary sclerosing cholangitis (n=11;6%) and 21.3%(n=39) had no known-risk factor. Intrahepatic CCA was the predominant type (n=73;39.9%), followed by distal (n=49;26.8%) and perihilar (n=38;20.8%). Regional lymph-node invasion was found in 74 (40.4%) and metastasis in 79 (43.2%) patients. Upon diagnosis, 88 patients (48.1%) required upfront biliary stenting prior to main treatments, consisting in resection (n=39;21.3%) or palliative modalities (n=135;73.8%). Recurrence occurred in 64.1%(n=25), with median time-to-recurrence of 13.5 months (95%CI:6.5-18.8). Chemotherapy was delivered to 120 patients (Gemcitabine+Cisplatin:n=105;87.5%) with a median progression-free survival of 4.2 months (95%CI:3.4-4.9). Median overall survival of the entire cohort was 8.2 months (n=183;95%CI:6.3-10.2), 22.5 (n=39;95%CI:11.6-34.1) under surgery, 10.4 (n=87;95%CI:8.4-13.6) under chemotherapy and 2.5 (n=30;95%CI:1.5-3.9) without active treatments (log-rank p<0.001). Conclusion: CCA is associated to diverse etiologies in Latin-America, particularly metabolic disorders. Surgical resection shows favorable outcome, highlighting the need of surveillance strategies in individuals at risk.http://www.sciencedirect.com/science/article/pii/S1665268121000752 |
| spellingShingle | Leonardo G. da Fonseca Laura Izquierdo-Sanchez Pedro H. Hashizume Estefanía Liza Beca Yanina Carlino Enrique Carrera Marco Arrese Javier Díaz Ferrer Domingo Balderramo Flair J. Carrilho Andre Boonstra Jose D. Debes Claudia Pinto Marques Souza de Oliveira Jesus M. Banales P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES Annals of Hepatology |
| title | P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES |
| title_full | P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES |
| title_fullStr | P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES |
| title_full_unstemmed | P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES |
| title_short | P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES |
| title_sort | p 10 latin american registry of cholangiocarcinoma clinical features management and outcomes |
| url | http://www.sciencedirect.com/science/article/pii/S1665268121000752 |
| work_keys_str_mv | AT leonardogdafonseca p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT lauraizquierdosanchez p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT pedrohhashizume p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT estefanializabeca p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT yaninacarlino p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT enriquecarrera p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT marcoarrese p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT javierdiazferrer p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT domingobalderramo p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT flairjcarrilho p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT andreboonstra p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT joseddebes p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT claudiapintomarquessouzadeoliveira p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes AT jesusmbanales p10latinamericanregistryofcholangiocarcinomaclinicalfeaturesmanagementandoutcomes |